The Institute for Clinical and Economic Review (ICER) recently released its first draft evidence report developed using Policy Analysis Inc.’s (PAI) hēRo3 economic modeling platform, PAI announced last week.
“We are pleased that ICER decided to use hēRo3 again in a new evidence review, as the organization is unquestionably the most important and influential health-technology assessment group in the U.S.,” PAI Managing Partner Gerry Oster said in a statement.
ICER’s director of health economics, Richard Chapman, said the platform saved the organization “substantial time,” and “will help us advance our ongoing initiative to further modeling transparency.”
To read the full press release, click here.
